These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Mar 20, 2014GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-small Cell Lung Cancer Misses First Co-primary EndpointsGSK to continue study until third co-primary endpoint is assessed
Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline’s (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in...
Mar 5, 2014Agenus to host conference call beginning at 11 a.m. ET today
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock...
Mar 5, 2014
Ludwig Cancer Research and Agenus Inc. (NASDAQ: AGEN) today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development....
Feb 27, 2014Agenus to Report Fourth Quarter and Year End 2013 Financial Results on March 5, 2014; Conference Call to Follow
Agenus Inc. (NASDAQ: AGEN) will release its fourth quarter and year end 2013 financial results before the market opens on March 5, 2014. Agenus executives will host a conference call at 11:00 a.m....
Feb 13, 2014Agenus gains powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets
Agenus Inc. (Nasdaq: AGEN), a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today...